GlassScriptPhysician profile
Timothy Jerum Clark
NPI 1518492008
$1,539.49
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,139 · 2022: $401.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $231.54 | 2021-2022 | |
| Novo Nordisk INC | $190.40 | 2021-2022 | |
| Medtronic, INC. | $182.40 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.47 | 2021-2022 | |
| Abbott Laboratories | $115.64 | 2021-2022 | |
| Lilly USA, LLC | $114.94 | 2021-2022 | |
| Dexcom, INC. | $80.75 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $65.57 | 2021 | |
| Corcept Therapeutics | $58.03 | 2022 | |
| Tandem Diabetes Care, INC. | $55.29 | 2021-2022 | |
| Becton, Dickinson and Company | $54.94 | 2021-2022 | |
| Amgen INC. | $44.62 | 2021 | |
| Insulet Corporation | $43.87 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.01 | 2021-2022 | |
| Mannkind Corporation | $34.84 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $27.48 | 2021 | |
| Alexion Pharmaceuticals, INC. | $25.20 | 2021 | |
| Xeris Pharmaceuticals, INC. | $19.04 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.46 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.